बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड और लोपिनाविर और रिटोनाविर का इंटरैक्शन

Concomitant administration of BIXLENVO is contraindicated with: dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events. strong CYP3A inducers due to decreased plasma concentrations of BIC and LEN, which may result in the loss of therapeutic effect and development of resistance to BIXLENVO.

Concomitant administration of BIXLENVO is contraindicated with: Dofetilide Strong CYP3A inducers.

Because BIXLENVO is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended ( 7.1 )

Concomitant administration of BIXLENVO with strong CYP3A inducers is contraindicated [see Contraindications (4) ] .

Concomitant administration of BIXLENVO with moderate CYP3A inducers is not recommended.

Patients who exhibit these signs or symptoms should be evaluated and KALETRA and/or other antiretroviral therapy should be suspended as clinically appropriate.

Elevated transaminases with or without elevated bilirubin levels have been reported in HIV-1 mono-infected and uninfected patients as early as 7 days after the initiation of KALETRA in conjunction with other antiretroviral agents.

Antimycobacterial: rifampin ↓ lopinavir Contraindicated due to potential loss of virologic response and possible resistance to KALETRA or to the class of protease inhibitors or other co-administered antiretroviral agents [see Contraindications ( 4 )] .